Riskpilot← Back to searchSign inGet full accessONCOSYNE AS
ASActiveOrg 926191942Ullernchausséen 64, 0379 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20206 employees
Revenue 2024
NOK 4,4M
+164% vs 2023
EBITDA margin
-42.3%
+42% vs 2023
Equity ratio
90.0%
Financial strength
Net profit 2024
NOK -1,7M
+45% vs 2023
| Revenue | NOK 4,4M | +164% |
| EBITDA | NOK -1,9M | +42% |
| Net profit | NOK -1,7M | +45% |
| Total assets | NOK 12M | +106% |
| Equity | NOK 10,8M | +107% |
| Employees | 6 | — |
Legal name
ONCOSYNE AS
Org number
926191942
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16. desember 2020
Share capital
NOK 1 124 801
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Forskning og utviklingsarbeid innen medisinsk bioteknologi med det formål å tilby legemiddelscreening som en diagnostisk tjeneste. Legemiddelscreenen skal være et beslutningsverktøy for skånsom, presis og effektiv kreftbehandling.
Address
Ullernchausséen 64, 0379 Oslo
Phone
+4741234614
Email
post@oncosyne.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 450 | 1 450 | 1 657 | 4 380 |
| Staff expenses | −0 | −0 | −1 034 | −2 200 | −2 688 |
| EBITDA | 0 | −202 | −1 252 | −3 169 | −1 854 |
| Depreciation & amort. | −0 | −0 | −40 | −18 | −127 |
| EBIT | 0 | −202 | −1 292 | −3 187 | −1 981 |
| Net financials | 0 | 6 | 11 | 46 | 260 |
| Profit before tax | 0 | −196 | −1 281 | −3 141 | −1 721 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −196 | −1 281 | −3 141 | −1 721 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 500 | 804 | 4 914 | 5 803 | 11 964 |
| Equity | 494 | 619 | 4 338 | 5 197 | 10 762 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 | 186 | 576 | 606 | 1 202 |
| Total debt | 6 | 186 | 576 | 606 | 1 202 |
EBITDA margin
-42.3%
This company
15.8%
Market median
-368% vs market
20202024
Equity ratio
90.0%
This company
38.2%
Market median
+136% vs market
20202024
Return on equity
-16.0%
This company
18.4%
Market median
-187% vs market
20202024
Net profit margin
-39.3%
This company
8.1%
Market median
-585% vs market
20202024
Asset turnover
0.37×
This company
1.12×
Market median
-67% vs market
20202024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BT Observer | Observer | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Deputy Chairman | 2022 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Kaarstad Smier As | Company | 31.1% | 31.1% | 2024 |
Norske Omveier As | Company | 31.1% | 31.1% | 2024 |
Wibo Consulting As | Company | 8.8% | 8.8% | 2024 |
Daedalus As | Company | 6.3% | 6.3% | 2024 |
Startuplab Founders Fund Iv As | Company | 5.9% | 5.9% | 2024 |
Millimedia As | Company | 4.2% | 4.2% | 2024 |
Fortress Fund 1 As | Company | 3.4% | 3.4% | 2024 |
Farvatn Venture As | Company | 2.5% | 2.5% | 2024 |
Svarthøi Holding As | Company | 1.8% | 1.8% | 2024 |
| Individual | 1.8% | 1.8% | 2024 | |
Jalco Consulting As | Company | 1.7% | 1.7% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Kaarstad Smier As
ONCOSYNE AS Board members of ONCOSYNE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Thomas Andersson | Observer | 0 companies |
| Ståle Bjørnstad | Board of Directors | 0 companies |
| John Edvard Karlsrud | Board of Directors | 0 companies |
| Øyvind Sverre Bruland | Board of Directors | 0 companies |
| Bjørn Olav Bakka | Board of Directors | 0 companies |
| Svenn Widerberg | Board of Directors | 0 companies |
| Jarle Bruun | Deputy Chairman | 0 companies |
| Peter Andreas Wold Eide | Chairman | 0 companies |
| Janne Merethe Nestvold | Board of Directors | 0 companies |